Li [45] concluded that DCN could inhibit or potentially treat hepatic fibrosis by reducing TGF-β1 levels in the hepatic tissues of Balb/c mice, thereby suppressing HSC activation, reducing ECM synthesis, and ultimately inhibiting or treating hepatic fibrosis induced by CCl4 in mice. Here, TGFB1 is linked to Hepatic fibrosis.